• Formycon signed cooperation agreements today with Biocelys and Santo Biosimilar to develop and commercialize a biosimilar candidate.
• Santo Biosimilar will finance the project in exchange for exclusive ownership of its development results.
• Rights and services to be provided under the collaboration, including interest, have an estimated fair value of EUR 40 million–45 million.
• Development and service work will earn hourly compensation with a low-double-digit margin, alongside service fees.
• A low-double-digit share of Santo Biosimilar’s revenue, net of project costs including interest, is expected to generate payments from 2036.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Formycon AG published the original content used to generate this news brief via EQS News (Ref. ID: RPT_2418974_de) on October 20, 2026, and is solely responsible for the information contained therein.